GlassScriptPhysician profile
Russell Pacquette
NPI 1447568597
$5,647.09
in general payments reported to CMS, 2019-2025
38 companies · $53.42 in 2025
The $53.42 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,456 · 2020: $1,063 · 2021: $1,792 · 2022: $1,120 · 2023: $143 · 2024: $20.28 · 2025: $53.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $217.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $828.01 | 2019-2022 | |
| Abbvie INC. | $549.81 | 2021-2022 | |
| Pfizer INC. | $537.88 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $520.42 | 2019-2023 | Farxiga |
| Amgen INC. | $464.64 | 2019-2023 | Otezla, Repatha |
| Astellas Pharma US INC | $455.63 | 2019-2023 | Myrbetriq |
| Sanofi-Aventis U.S. LLC | $351.50 | 2019-2023 | |
| Lilly USA, LLC | $270.98 | 2019-2022 | |
| Esperion Therapeutics, INC. | $171.20 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $146.64 | 2021-2022 | |
| Dexcom, INC. | $141.71 | 2021-2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.18 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $95.29 | 2021 | |
| Glaxosmithkline, LLC. | $88.07 | 2021-2022 | |
| Allergan, INC. | $87.94 | 2019-2020 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Pacquette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.